Altmetrics
Downloads
149
Views
186
Comments
0
A peer-reviewed article of this preprint also exists.
supplementary.pdf (378.09KB )
This version is not peer-reviewed
Submitted:
13 February 2024
Posted:
13 February 2024
You are already at the latest version
Childhood glaucoma Alleles (%) [n=202] | ESP6500* Alleles (%) [n=8600] | gnomAD* v2.1.1 Alleles (%) [n=104400] | p-Value (Chi-square test) (CG vs. ESP6500) | p-Value (Chi-square test) (CG vs. gnomAD v2.1.1) | Odds Ratio (95% CI) (CG vs. ESP6500) | Odds Ratio (95% CI) (CG vs. gnomAD v2.1.1 | ||
---|---|---|---|---|---|---|---|---|
Aggregate genes | Rare frameshift, non-sense, missense and donor/acceptor splicing sites | 59 (29.20) | 854 (10.03) | 9489 (9.13) | <1E-15 | <1E-15 | 3.49 (2.56-4.77) | 4.06 (3.00-5.50) |
Rare Synonymous | 17 (8.42) | 773 (9.05) | 10584 (9.83) | 6.39E-01 | 5.77E-01 | 0.86 (0.52-1.42) | 0.84 (0.51-1.39) | |
ADAMTS2 | Rare frameshift, non-sense, missense and donor/acceptor splicing sites | 14 (6.93) | 140 (1.63) | 1611 (1.56) | 6.52E-08 | 5.00E-09 | 4.49 (2.55-7.93) | 4.70 (2.72-8.10) |
Rare Synonymous | 2 (0.99) | 184 (2.15) | 2616 (2.43) | 3.79E-01 | 2.70E-01 | 0.46 (0.11-1.85) | 0.40 (0.10-1.61) | |
ADAMTS18 | Rare frameshift, non-sense, missense and donor/acceptor splicing sites | 14 (6.93) | 178 (2.07) | 2953 (2.70) | 9.47E-06 | 5.01E-04 | 3.52 (2.01-6.18) | 2.68 (1.56-4.62) |
Rare Synonymous | 3 (1.49) | 158 (1.84) | 2110 (1.93) | 9.17E-01 | 8.36E-01 | 0.81 (0.25-2.55) | 0.76 (0.24-2.39) | |
ADAMTSL4 | Rare frameshift, non-sense, missense and donor/acceptor splicing sites | 16 (7.92) | 176 (2.05) | 2213 (2.06) | 6.97E-08 | 2.08E-08 | 4.10 (2.41-6.99) | 4.10 (2.45-6.84) |
Rare Synonymous | 3 (1.49) | 83 (0.97) | 1545 (1.41) | 7.09E-01 | 8.31E-01 | 1.54 (0.48-4.91) | 1.05 (0.34-3.29) | |
CPAMD8 | Rare frameshift, non-sense, missense and donor/acceptor splicing sites | 15 (7.43) | 360 (4.34) | 2712 (2.84) | 5.24E-02 | 2.13E-04 | 1.77 (1.04-3.03) | 2.75 (1.62-4.65) |
Rare Synonymous | 9 (4.46) | 348 (4.19) | 4313 (4.20) | 9.92E-01 | 9.94E-01 | 1.07 (0.54-2.10) | 1.06 (0.55-2.08) |
Patient | ADAMTS2 | ADAMTS18 | ADAMTSL4 | CPAMD8 | Total number ofvariants per patient | Age at diagnosis (months) | IOP at diagnosis (mm Hg) (RE/LE) | Cup/discratio(RE/LE) | Surgical treatment (# surgeries) | Gender/laterality | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PCG67-GI | p.Glu188Gln | p.Gln146His | 2 | 144 | 47/37 | 0.4/0.3 | T (4), C/T (6), V, C | ||||||||||
PCG85 | p.Pro932Leu | p.Asp746Glu | 2 | 10 | NA | NA | G/G (2), T (2) | M/B | |||||||||
PCG87 | p.Pro29Serp.Leu23Pro | 2 | 16 | 48/42 | 0.8/0.8 | G/G | M/B | ||||||||||
PCG103 | p.Arg1862Glnp.Ala1492Pro | 2 | 8 | NA | NA | G/G | F/B | ||||||||||
PCG143 | p.Asn312Serp.Leu23Pro | p.Arg1090Ser | 3 | 60 | NA | NA | None | F/B | |||||||||
PCG219 | p.Pro195Leu | p.Ala1267Thr | 2 | 5 | NA | NA | T/T | F/B | |||||||||
PCG291 | p.Val1073Ilep.Gly336Asp | p.Ile823Val | 3 | 36 | NA | NA | G/G | M/B |
Variable | MMP-related gene carriers (A) | MMP-related gene non-carriers (B) | PCGs with null CYP1B1 genotypes (n=37) (C) | P (A vs. B) | p (A vs. C) | p (B vs. C) |
---|---|---|---|---|---|---|
aAge at diagnosis (months)(mean±SD) | 17.1±37.4 (n=50) | 12.18±25.2 (n=28) | 1.9±5.2 | ns | 0.0075 | 0.0089 |
Number of surgeries per eye(mean±SD) | 1.9±1.4 (n=47) | 0.8±1.40 (n=31) | 3.1±1.7 | 0.001 | 0.0014 | 0.00000019 |
IOP at diagnosis (mm Hg) (mean±SD) | 30.0±1.4(n=48) | 30.5±9.3(n=30) | 28.0±5.5 | ns | ns | ns |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated